1011-00004 · Meridian Consumer Brands LLC · Pleadings

draft-verified-complaint.docx DOCUMENT Litigation

10 / 12 ← → ✕

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

VERIFIED COMPLAINT FOR INJUNCTIVE RELIEF, DAMAGES, AND OTHER RELIEF

Matter No. 1011-00004

Right-click to update Table of Contents

INTRODUCTION

1. This is an action for false advertising, deceptive business practices, unfair competition, and tortious interference with business relations brought by Plaintiff Meridian Consumer Brands LLC ("Meridian" or "Plaintiff") against Defendant Apex Naturals Inc. ("Apex" or "Defendant") arising from Apex's nationwide comparative advertising campaign known as "The PuraClear Truth," which Apex launched on or about June 2, 2025. Meridian brings this action to halt Apex's ongoing campaign of deception, to obtain redress for the substantial injuries Meridian has already suffered, and to prevent further irreparable harm to Meridian's brand, business, and consumer relationships.

2. Beginning on or about June 2, 2025, Apex launched a multi-channel comparative advertising campaign under the name "The PuraClear Truth," which has been disseminated across national television (including 30-second and 60-second commercial spots airing during prime-time and daytime programming), digital video platforms (including Crowne Albany Partners LLC, Dunmore & Co., and Northpoint Services Inc. Reels), in-store point-of-sale displays at major drugstore chains throughout the United States, print advertisements placed in widely circulated consumer magazines, and a dedicated campaign page hosted on Apex's corporate website at www.apexnaturals.com/puraclear-truth. Upon information and belief, Apex's total estimated media spend for the campaign during the period of June through August 2025 was approximately $23.0 million, comprising approximately $14.3 million in national television advertising expenditures and approximately $8.7 million in digital and social media advertising expenditures. The scope, reach, and intensity of this campaign underscore the deliberateness of Apex's scheme and the magnitude of the harm it has inflicted and continues to inflict upon Meridian.

3. The campaign makes three categories of materially false and misleading claims about Apex's "PuraClear" acne-treatment product line relative to Meridian's flagship "DermaTrūe" product family. First, the campaign asserts a fabricated clinical superiority claim, purportedly based on a peer-reviewed study that does not exist, stating that PuraClear reduces visible acne blemishes "47% faster" than DermaTrūe. Second, the campaign features a deliberately misleading apples-to-oranges price comparison that juxtaposes the price of a single 1.0 oz. PuraClear tube against the price of a multi-product, 5.2 oz. DermaTrūe regimen kit, creating the false impression that DermaTrūe is overpriced when, in fact, DermaTrūe is significantly less expensive on a per-ounce basis. Third, the campaign falsely claims that DermaTrūe products contain parabens, sulfates, and synthetic fragrances, when Meridian's reformulated DermaTrūe Pure products are entirely free of all such ingredients — a fact independently verified by a third-party laboratory. Each of these categories of false claims is designed to deceive consumers and divert sales from Meridian to Apex.

4. As a direct and proximate result of Apex's false and deceptive campaign, Meridian has suffered — and continues to suffer — substantial and ongoing harm. DermaTrūe revenue declined from $36.8 million in the third quarter of fiscal year 2024 to $29.4 million in the third quarter of fiscal year 2025, representing a year-over-year decline of $7.4 million, or 20.1%. Consumer survey data demonstrates severe brand-perception damage: the percentage of consumers who perceive DermaTrūe as "overpriced" increased by 23 percentage points following the launch of the campaign, and the percentage who believe DermaTrūe is "less effective" than PuraClear increased by 19 percentage points. Moreover, on August 5, 2025, Kingsley Drug Stores LLC ("Kingsley"), a major national drugstore chain operating more than 2,400 retail locations, notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025, citing declining consumer demand — demand that declined as a direct result of Apex's false advertising. The damage to Meridian's brand reputation, retail relationships, and consumer trust is ongoing, is escalating, and cannot be fully remedied through monetary damages alone.

5. By this Complaint, Meridian brings claims under Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a); New York General Business Law §§ 349 and 350; and the common law of the State of New York, including claims for unfair competition and tortious interference with business relations. Meridian seeks preliminary and permanent injunctive relief ordering Apex to immediately and permanently cease its false advertising campaign; compensatory damages for Meridian's lost profits; disgorgement of Apex's ill-gotten profits attributable to the false advertising; treble damages in light of Apex's willful conduct; an order requiring Apex to fund and disseminate corrective advertising sufficient to dispel the false impressions created by the campaign; and an award of Meridian's reasonable attorneys' fees and costs.

PARTIES

A. Plaintiff Meridian Consumer Brands LLC

6. Plaintiff Meridian Consumer Brands LLC is a limited liability company duly organized and existing under the laws of the State of Delaware and registered to do business in the State of New York. Meridian maintains its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001.

7. Meridian is principally engaged in the development, marketing, and retail distribution of premium skincare, personal-care, and over-the-counter dermatological products throughout the United States and in select international markets. Meridian's portfolio of consumer brands includes DermaTrūe, a leading acne and blemish treatment line; Velara, an anti-aging skincare collection; and SkinSense, a line of products formulated for sensitive skin. Meridian's products are sold through major national and regional retail chains, specialty beauty retailers, and e-commerce platforms, and are available in thousands of retail locations across the country.

8. For the fiscal year ending December 31, 2024, Meridian's total annual revenue was approximately $487.6 million, as reported in Meridian's audited financial statements prepared by Ashford & Kline LLP, Certified Public Accountants. The DermaTrūe product line is Meridian's largest individual brand by revenue, having generated approximately $138.2 million in revenue during fiscal year 2024, representing approximately 28.3% of Meridian's total revenue. The DermaTrūe brand is a cornerstone of Meridian's business and represents years of investment in product development, clinical testing, brand building, and consumer trust.

9. Meridian is a portfolio company of Brindoval Capital Partners Fund IV LP, a Delaware limited partnership, which acquired Meridian in 2019. Since Brindoval's acquisition, Meridian has invested significantly in product innovation, brand development, and market expansion, including the 2024 reformulation and relaunch of the DermaTrūe line as "DermaTrūe Pure."

10. Meridian's senior leadership includes Nathan Hartwell, Chief Executive Officer; Julia Whitmore, Chief Marketing Officer; Derek Cho, General Counsel; and Dr. Annika Patel, Vice President, Regulatory and Scientific Affairs. Each of these individuals has personal knowledge of the facts alleged in this Complaint.

B. Defendant Apex Naturals Inc.

11. Defendant Apex Naturals Inc. is a corporation duly organized and existing under the laws of the State of Delaware, with its principal place of business at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex's registered agent for service of process in Delaware is Pinnacle Registered Agents LLC, located at 1209 Orange Street, Wilmington, Delaware 19801. Upon information and belief, Apex is authorized to transact business in the State of New York and regularly does so.

12. Apex is principally engaged in the development, manufacturing, marketing, and sale of mass-market and "clean-beauty" skincare and acne-treatment products, which are sold primarily through national drugstore chains, mass-market retail outlets, and e-commerce channels, including Apex's own direct-to-consumer website. Apex's portfolio of consumer brands includes PuraClear, an acne treatment line that directly competes with Meridian's DermaTrūe products; GreenVeil, a line of moisturizers; and ClearPath, a line of body wash products. PuraClear is Apex's largest individual brand and its primary competitive offering in the acne-treatment category.

13. Upon information and belief, Apex's estimated total annual revenue for the fiscal year ending December 31, 2024, was approximately $312.4 million. The PuraClear product line generated an estimated $89.7 million in revenue during fiscal year 2024, representing approximately 28.7% of Apex's total revenue. DermaTrūe and PuraClear are direct competitors in the acne-treatment market, competing for the same consumers, the same retail shelf space, and the same market share.

14. Apex's senior leadership includes Marcus Devlin, Founder and Chief Executive Officer; Rachel Emory, Chief Marketing Officer; Dr. Simon Guerrero, Vice President, Product Development; and Tanya Fischetti, General Counsel. Upon information and belief, Mr. Devlin, Ms. Emory, and Dr. Guerrero were each personally involved in the development, approval, and dissemination of "The PuraClear Truth" campaign that is the subject of this Complaint.

JURISDICTION AND VENUE

15. Subject Matter Jurisdiction — Federal Question. This Court has original subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1331 because this action arises under the laws of the United States, specifically Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a), which provides a federal cause of action for false advertising and unfair competition in interstate commerce. The amount in controversy exceeds $75,000, exclusive of interest and costs.

16. Supplemental Jurisdiction. This Court has supplemental jurisdiction over Plaintiff's state-law claims — including claims under New York General Business Law §§ 349 and 350, and Plaintiff's common-law claims for unfair competition and tortious interference with business relations — pursuant to 28 U.S.C. § 1367(a), because those claims are so related to the federal Lanham Act claim as to form part of the same case or controversy under Article III of the United States Constitution. The state-law claims arise from the same nucleus of operative fact as the federal claim, namely, Apex's nationwide false advertising campaign targeting Meridian's DermaTrūe products.

17. Personal Jurisdiction. Defendant Apex Naturals Inc. is subject to personal jurisdiction in this judicial district. Apex has purposefully directed its advertising campaign — including the false and misleading "The PuraClear Truth" campaign — at consumers throughout the State of New York. National television advertisements containing the false claims have been broadcast to and received by consumers in this district. Digital advertisements have been served to and viewed by consumers in this district through Crowne Albany Partners LLC, Dunmore & Co., Northpoint Services Inc. Reels, and other online platforms. In-store point-of-sale displays featuring the false claims have been placed in drugstore locations throughout the State of New York, including in this district. Print advertisements have been distributed in consumer magazines circulated in this district. The campaign page on Apex's website at www.apexnaturals.com/puraclear-truth is accessible to and has been accessed by consumers in this district. Moreover, upon information and belief, Apex regularly conducts business in New York, ships products to retailers and consumers in New York, and derives substantial revenue from sales in New York. Apex's contacts with this forum are sufficient to establish both general and specific personal jurisdiction under New York's long-arm statute, N.Y. C.P.L.R. § 302(a), and are consistent with the requirements of the Due Process Clause of the Fourteenth Amendment.

18. Venue. Venue is proper in this judicial district pursuant to 28 U.S.C. § 1391(b)(2) because a substantial part of the events or omissions giving rise to the claims asserted herein occurred in this district. The false advertisements at issue have been disseminated to, received by, and have impacted consumers and retailers in this district. Plaintiff Meridian maintains its principal place of business in this district, and the harm to Meridian's business, brand reputation, and retail relationships has been felt acutely in this district. Venue is also proper under 28 U.S.C. § 1391(b)(1) because Apex is subject to personal jurisdiction in this district.

FACTUAL ALLEGATIONS

A. Meridian's DermaTrūe Product Line

19. Meridian has developed, manufactured, and marketed the DermaTrūe product family since 2011, when the line was first introduced to the market as a premium acne and blemish treatment system. Over the past fourteen years, Meridian has invested tens of millions of dollars in research and development, clinical testing, regulatory compliance, brand building, and marketing to establish DermaTrūe as one of the leading acne-treatment brands in the United States. The current DermaTrūe product line includes a range of products formulated to address various types and severities of acne. The flagship product offering is the DermaTrūe Complete Acne System, a three-piece regimen kit containing a 2.0 oz. facial cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer, for a combined total of 5.2 oz. of product. The DermaTrūe Complete Acne System retails at a manufacturer's suggested retail price ("MSRP") of $28.99, which equates to a per-ounce price of approximately $5.57. The DermaTrūe line also includes individual products such as DermaTrūe Daily Cleanser, DermaTrūe Intensive Treatment Gel, DermaTrūe Oil-Free Moisturizer, and DermaTrūe Overnight Repair Serum, all of which are competitively priced within the premium acne-treatment segment.

20. In 2024, Meridian undertook a comprehensive reformulation and relaunch of the DermaTrūe product line under the name "DermaTrūe Pure." The reformulation was driven by consumer demand for "clean-beauty" products and involved the removal of all parabens, sulfates, and synthetic fragrances from every product in the DermaTrūe line, while maintaining the same clinically validated active-ingredient profiles and efficacy standards. Meridian invested approximately $6.2 million in the reformulation process, including ingredient sourcing, stability testing, consumer trials, and regulatory review. The reformulated ingredient profile of every DermaTrūe Pure product was independently tested and confirmed by Beacon Scientific Laboratories LLC ("Beacon Scientific"), an accredited independent testing laboratory, in Lab Report No. BSL-2025-0412, dated March 15, 2025. Beacon Scientific's testing confirmed that the DermaTrūe Pure products are free of all parabens (including methylparaben, ethylparaben, propylparaben, butylparaben, and isobutylparaben), free of all sulfates (including sodium lauryl sulfate and sodium laureth sulfate), and free of all synthetic fragrances. The DermaTrūe Pure product line has been on the market and available at retail since April 2024.

21. The DermaTrūe line is a cornerstone of Meridian's business and its single largest source of revenue. In fiscal year 2024, the DermaTrūe product line generated approximately $138.2 million in revenue, representing approximately 28.3% of Meridian's total revenue of $487.6 million. DermaTrūe products carry a blended gross margin of approximately 62.5%, reflecting the premium positioning, high-quality ingredients, and strong consumer demand for the brand. DermaTrūe is Meridian's most profitable product line and a critical driver of the company's overall financial performance.

22. Meridian has invested substantial time, resources, and capital in building the DermaTrūe brand's reputation among consumers, dermatologists, and retail partners for quality, efficacy, safety, and value. Meridian has spent an average of approximately $22 million per year over the past five years on DermaTrūe-related advertising, marketing, and promotional activities, including national television advertising, digital marketing, influencer partnerships, point-of-sale materials, and trade marketing programs with retail partners. As a result of these sustained investments, DermaTrūe has achieved strong brand recognition, consumer loyalty, and retailer confidence, all of which constitute valuable goodwill that Apex's false advertising campaign has damaged and continues to damage.

B. Apex's "The PuraClear Truth" Campaign

23. On or about June 2, 2025, Defendant Apex Naturals Inc. launched a nationwide comparative advertising campaign under the name "The PuraClear Truth." Upon information and belief, the campaign was referred to internally at Apex as "Project Clarity." The campaign was conceived, developed, and produced by Brightline Creative Partners LLC ("Brightline"), an advertising agency headquartered at 55 Washington Street, Suite 900, Brooklyn, New York 11201, under the creative direction of Owen Prescott, Brightline's Chief Creative Officer. Upon information and belief, the campaign strategy was approved at the highest levels of Apex's management, including by Marcus Devlin, Apex's CEO and Founder; Rachel Emory, Apex's CMO; and Dr. Simon Guerrero, Apex's VP of Product Development.

24. "The PuraClear Truth" campaign has been disseminated broadly across multiple media channels, ensuring maximum reach among the target consumer audience for acne-treatment products. The campaign includes 30-second and 60-second television commercial spots that have aired on national broadcast and cable networks during prime-time, daytime, and weekend programming blocks. The campaign also includes digital video advertisements distributed through Crowne Albany Partners LLC (both pre-roll and mid-roll placements), Dunmore & Co. (sponsored content and in-feed advertisements), and Northpoint Services Inc. Reels (sponsored placements and story advertisements). In addition, Apex has distributed in-store point-of-sale displays — including shelf talkers, end-cap displays, and countertop displays — at major drugstore chains throughout the United States, including at retail locations in the State of New York and in this judicial district. The campaign further includes print advertisements placed in widely circulated consumer magazines, including publications focused on health, beauty, and lifestyle. Finally, Apex has maintained a dedicated campaign page on its corporate website at www.apexnaturals.com/puraclear-truth, which consolidates the campaign's messaging, video content, and claims in a single, publicly accessible location.

25. Upon information and belief, the estimated total media spend for "The PuraClear Truth" campaign during the period of June through August 2025 was approximately $23.0 million. Of this total, approximately $14.3 million was allocated to national television advertising placements, and approximately $8.7 million was allocated to digital and social media advertising placements. The scale of this media investment reflects a deliberate and aggressive strategy to saturate the market with the campaign's false claims, maximize consumer exposure to those claims, and inflict maximum competitive damage on Meridian's DermaTrūe brand.

26. The campaign expressly and prominently names and targets Meridian's DermaTrūe product line by name. Throughout the campaign materials — including television spots, digital videos, in-store displays, print advertisements, and the campaign website — DermaTrūe is identified by name and used as a point of comparison to promote PuraClear's purported advantages. The campaign does not merely make general claims about PuraClear; it specifically and repeatedly attacks DermaTrūe's efficacy, pricing, and ingredient profile through false and misleading comparative claims. The targeting of DermaTrūe by name was a deliberate strategic decision designed to divert DermaTrūe's loyal customer base to PuraClear.

C. The False Clinical Superiority Claim

27. A central and prominently featured claim in "The PuraClear Truth" campaign is a purported clinical superiority claim. The campaign prominently states, across television spots, digital advertisements, in-store displays, and the campaign website: "In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment." The advertisement further cites the purported source study as "Guerrero et al., 2024, Independent Dermatological Review." This citation appears on-screen during television and digital video advertisements as a superimposed text citation, is printed in fine print on in-store point-of-sale displays, and is included in a footnote on the campaign website. The citation is formatted and presented in the style of a legitimate academic journal citation, and is designed to convey to consumers the impression that the 47% superiority claim is supported by an independent, rigorous, peer-reviewed scientific study.

28. Upon information and belief, no study authored by "Guerrero et al." was published in 2024 — or at any other time — in any peer-reviewed journal. Upon further information and belief, no journal titled Independent Dermatological Review exists as a recognized peer-reviewed dermatological or scientific publication. A thorough search of major academic databases, including PubMed, Hollowell Data Systems, Web of Science, and the National Library of Medicine catalog, has revealed no record of any journal bearing that title, and no record of any published study matching the cited authorship, date, or findings. The citation is fabricated.

29. Upon information and belief, the only testing that Apex conducted or caused to be conducted in connection with any comparison between PuraClear and DermaTrūe products was a non-blinded, 22-person pilot study that lacked a placebo control group, was not randomized, and did not employ any of the methodological safeguards — including blinding, randomization, adequate sample size, and statistical controls — that are necessary to satisfy generally accepted standards for clinical research design in dermatology. A 22-person pilot study without a control group does not and cannot substantiate the claim that PuraClear reduces acne blemishes "47% faster" than DermaTrūe or any other specific competitive product. The results of such a study are not statistically significant, are not generalizable, and do not constitute competent and reliable scientific evidence.

30. It is notable and telling that Dr. Simon Guerrero — Apex's own Vice President of Product Development — is the named lead author on the purported study cited in the campaign. Dr. Guerrero is a salaried employee of Apex with a direct financial interest in the success of the PuraClear brand. The fact that the purported study's lead author is an Apex executive further underscores that the study was neither independent nor published in any legitimate peer-reviewed journal, notwithstanding the campaign's deliberate use of the word "Independent" in the title of the fabricated journal to create a false impression of objectivity.

31. The clinical superiority claim contained in "The PuraClear Truth" campaign — that "PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment" — is literally false. It purports to be based on a published, peer-reviewed clinical study that does not exist. Alternatively, and at a minimum, the claim is misleading to a substantial portion of the relevant consumer audience because it creates the false impression that PuraClear's superiority over DermaTrūe has been scientifically established through rigorous, independent clinical research, when in fact no competent and reliable scientific evidence supports the claim. In either case, the claim is materially deceptive and is the type of claim that has the tendency to influence consumers' purchasing decisions.

D. The False Price Comparison Claim

32. Another prominent claim in "The PuraClear Truth" campaign is a comparative price claim. The campaign states, across television spots, digital advertisements, in-store displays, and the campaign website: "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit." This claim is presented with visual side-by-side comparisons of the two products, with the PuraClear product displayed alongside a price of "$12.99" and the DermaTrūe product displayed alongside a price of "$28.99," creating a stark and visually compelling — but fundamentally misleading — impression of a dramatic price disparity.

33. This price comparison is materially misleading because it compares non-comparable products of vastly different sizes, compositions, and intended uses. The PuraClear product cited at $12.99 is a single 1.0 oz. tube of PuraClear Spot Treatment — a single-purpose product designed for targeted application to individual blemishes. The DermaTrūe product cited at $28.99 is the DermaTrūe Complete Acne System — a comprehensive three-piece regimen kit containing a 2.0 oz. cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer, for a combined total of 5.2 oz. of product. The DermaTrūe Complete Acne System includes three distinct products designed to be used together as part of a comprehensive daily skincare regimen, while the PuraClear Spot Treatment is a single product with a single function. The two products are not "comparable" in any meaningful sense — not in size, not in composition, not in functionality, and not in the scope of treatment they provide.

34. On a per-ounce basis — the standard and accepted metric for comparing the prices of consumer products of different sizes — the DermaTrūe Complete Acne System costs approximately $5.57 per ounce ($28.99 ÷ 5.2 oz.), while the PuraClear Spot Treatment costs $12.99 per ounce ($12.99 ÷ 1.0 oz.). The PuraClear product is thus more than double the price of the DermaTrūe product on a per-ounce basis — more than 2.3 times the per-ounce cost. The campaign's claim that PuraClear is available at "half the price" of a "comparable" DermaTrūe product is not merely misleading; it is the precise opposite of the truth when measured on any fair, industry-standard unit-price basis. The price comparison turns reality on its head, portraying the less expensive product (DermaTrūe, on a per-ounce basis) as the more expensive one, and vice versa.

35. The campaign deliberately and knowingly exploits the difference between the absolute retail price of a multi-product regimen kit and the absolute retail price of a single small tube to manufacture the false impression that DermaTrūe products are overpriced relative to PuraClear. This is a classic and well-recognized form of misleading price comparison — comparing a large format or bundled product to a small, single-unit product — and Apex employs it here with full knowledge that the comparison is unfair, misleading, and designed to deceive consumers. The false price comparison is particularly harmful because price sensitivity is a major driver of consumer purchasing decisions in the acne-treatment category, and the false impression that DermaTrūe is overpriced directly undermines Meridian's competitive position and brand equity.

E. The False "Clean" Ingredients Claim

36. The third category of false claims in "The PuraClear Truth" campaign involves a comparative "clean" ingredients claim. The campaign states, across television spots, digital advertisements, in-store displays, and the campaign website: "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances." The use of the word "Unlike" is specifically intended to communicate to consumers that DermaTrūe products do contain parabens, sulfates, and/or synthetic fragrances — ingredients that have been the subject of significant consumer concern and negative media coverage in recent years. The claim is designed to exploit consumer anxiety about these ingredients and to position PuraClear as a safer, cleaner alternative to DermaTrūe.

37. This claim is false. As set forth above, Meridian reformulated and relaunched the DermaTrūe product line in 2024 as "DermaTrūe Pure," and every product in the current DermaTrūe Pure line is free of parabens, free of sulfates, and free of synthetic fragrances. This has been independently confirmed by Beacon Scientific Laboratories LLC, an accredited independent testing laboratory, in Lab Report No. BSL-2025-0412, dated March 15, 2025. Beacon Scientific conducted comprehensive ingredient testing of representative samples from every product in the DermaTrūe Pure line and confirmed the absence of all parabens (including methylparaben, ethylparaben, propylparaben, butylparaben, and isobutylparaben), all sulfates (including sodium lauryl sulfate and sodium laureth sulfate), and all synthetic fragrances. The DermaTrūe Pure reformulation has been on the market for over a year, and the ingredient lists for all DermaTrūe Pure products — which are printed on the product packaging and publicly available — clearly reflect the absence of these ingredients.

38. Apex's claim that DermaTrūe contains parabens, sulfates, and/or synthetic fragrances — and that PuraClear is superior or unique in being free of these ingredients — is literally false. There is no factual basis for the claim, and Apex either knew or should have known that the claim was false at the time it launched the campaign. A simple review of DermaTrūe Pure's publicly available ingredient lists, or a basic inquiry directed to Meridian, would have revealed that the claim was untrue. The false "clean" ingredients claim misleadingly implies that consumers choosing DermaTrūe are exposing their skin to ingredients — specifically parabens, sulfates, and synthetic fragrances — that have been the subject of widespread consumer safety concerns and negative publicity. This false implication is particularly damaging because it strikes at the heart of Meridian's significant investment in reformulating its product line to meet consumer demand for clean-beauty products, and because ingredient safety is a deeply important and emotionally charged issue for consumers in the skincare market.

F. Pre-Litigation Efforts

39. Meridian has made extensive efforts to resolve this dispute prior to filing this action. On June 18, 2025 — just sixteen days after the launch of "The PuraClear Truth" campaign — Meridian's General Counsel, Derek Cho, sent a detailed cease-and-desist letter to Apex's General Counsel, Tanya Fischetti, via certified mail and email. The letter identified each of the three categories of false claims, provided supporting evidence that the claims were false, and demanded that Apex immediately withdraw all "The PuraClear Truth" advertisements across all media channels, issue a public retraction of the false claims, and confirm in writing its commitment not to repeat the false claims in the future. The letter set a response deadline of July 2, 2025.

40. On July 3, 2025 — one day after the stated deadline — Apex responded through its outside counsel, Harrison Briggs of Caldwell, Briggs & Nolan LLP, 200 Park Avenue, 42nd Floor, New York, New York 10166. In its response, Apex categorically denied all of the allegations set forth in Meridian's cease-and-desist letter. Apex asserted, without providing any supporting documentation, that all claims in "The PuraClear Truth" campaign are "truthful, substantiated, and protected by the First Amendment." Apex refused to withdraw, modify, or retract any aspect of the campaign and stated that it intended to continue the campaign as planned. At no point during the exchange did Apex produce the purported "Guerrero et al., 2024" study or any other documentation substantiating its clinical superiority claim.

41. Having failed to resolve the matter through direct communication with Apex, Meridian pursued self-regulatory relief. On July 22, 2025, Meridian filed a formal complaint with the National Advertising Division ("NAD") of the Better Business Bureau's National Programs, challenging the clinical superiority claim, the price-comparison claim, and the "clean" ingredients claim. The NAD proceeding was assigned Case Reference No. NAD-2025-01847.

42. On August 15, 2025, following an expedited review, NAD issued a preliminary recommendation that Apex discontinue or substantially modify both the clinical superiority claim and the price-comparison claim pending further substantiation. Specifically, NAD found that Apex had failed to provide adequate substantiation for the claim that PuraClear reduces visible acne blemishes "47% faster" than DermaTrūe, and that the price comparison between a 1.0 oz. single product and a 5.2 oz. multi-product kit was misleading and lacked adequate context to prevent consumer confusion. NAD deferred its recommendation on the "clean" ingredients claim pending additional information.

43. Rather than comply with the NAD's recommendation, Apex publicly stated on August 18, 2025, through a press release issued on its corporate website, that it would appeal the NAD recommendation and that it "stands behind the accuracy and integrity of 'The PuraClear Truth' campaign." Apex declined to modify any aspect of the campaign. As of the date of filing of this Complaint, Apex has continued to disseminate "The PuraClear Truth" advertisements without modification across all media channels, including national television, digital platforms, in-store displays, print media, and the campaign website. Apex's refusal to comply with the NAD's preliminary recommendation confirms that self-regulatory mechanisms are insufficient to address the ongoing harm caused by Apex's false advertising, and that judicial intervention is necessary.

G. Harm to Meridian

1. Revenue Decline

44. As a direct and proximate result of Apex's false advertising campaign, DermaTrūe revenue has declined sharply. In the third quarter of fiscal year 2024 (July through September 2024) — the last full quarter before the launch of "The PuraClear Truth" campaign — DermaTrūe generated revenue of approximately $36.8 million. In the third quarter of fiscal year 2025 (July through September 2025) — the first full quarter following the launch of the campaign — DermaTrūe revenue declined to approximately $29.4 million. This represents a year-over-year revenue decline of approximately $7.4 million, or 20.1%. This precipitous decline occurred during what should have been a period of stable or growing revenue, given the strong performance of the DermaTrūe line in prior periods, the successful relaunch of DermaTrūe Pure, and the absence of any other material changes in the competitive landscape that would account for such a severe decline.

45. At DermaTrūe's blended gross margin of approximately 62.5%, the Q3 2025 revenue decline of $7.4 million translates to lost gross profit of approximately $4.625 million for the quarter. If Apex's false advertising campaign is permitted to continue unchecked, Meridian's annualized lost gross profit attributable to the campaign is conservatively estimated at approximately $18.5 million ($4.625 million × 4 quarters). This estimate is conservative because it does not account for the compounding effects of continued brand-perception damage, additional potential retail shelf-space reductions, or the erosion of consumer loyalty that is likely to accelerate over time as the false claims continue to be disseminated.

2. Brand-Perception Damage

46. In order to quantify the impact of Apex's false advertising on consumer perceptions of the DermaTrūe brand, Meridian retained Dr. Eleanor Fisk of Fisk Analytics Group LLC, an independent consumer-research and market-analytics firm located at 101 Federal Street, Suite 2600, Boston, Massachusetts 02110, to conduct a consumer-perception survey. Dr. Fisk is a recognized expert in consumer survey research methodology and has served as a survey expert in numerous false-advertising and trademark litigation matters. The post-campaign survey was designed and fielded on August 22, 2025, using a nationally representative sample of 1,500 adults aged 18 and older, with oversampling of consumers who had purchased acne-treatment products within the prior twelve months. The survey had a margin of error of ±2.5 percentage points at the 95% confidence level.

47. Dr. Fisk's post-campaign survey produced striking and deeply concerning results. Among respondents who recalled seeing or hearing "The PuraClear Truth" advertisements, 34% agreed with the statement that DermaTrūe products are "overpriced," compared to only 11% of respondents in a baseline survey conducted by Dr. Fisk in January 2025 — before the launch of Apex's campaign. This represents a 23-percentage-point increase in the proportion of consumers who perceive DermaTrūe as overpriced, an increase that is directly attributable to Apex's false price-comparison claim. Additionally, among respondents who recalled the advertisements, 27% agreed with the statement that DermaTrūe is "less effective than PuraClear," compared to only 8% in the January 2025 baseline survey — a 19-percentage-point increase that is directly attributable to Apex's fabricated clinical superiority claim. These shifts in consumer perception are statistically significant, substantively dramatic, and highly damaging to Meridian's brand.

48. The survey results demonstrate that Apex's false claims have materially and measurably altered consumer perceptions of DermaTrūe in ways that are profoundly harmful to Meridian. Consumer perceptions of product efficacy and value are among the most important drivers of purchasing decisions in the skincare market, and the false impressions created by Apex's campaign are difficult or impossible to reverse through monetary damages alone. Even if Apex were to immediately cease the campaign, the false impressions that DermaTrūe is overpriced and less effective than PuraClear have already been planted in the minds of millions of consumers and will continue to suppress DermaTrūe sales for an extended period. This ongoing and potentially irreversible harm to Meridian's brand equity underscores the urgent need for injunctive relief, including corrective advertising.

3. Retail Shelf-Space Loss

49. On August 5, 2025, Kingsley Drug Stores LLC ("Kingsley"), a major national retail chain operating more than 2,400 stores across 42 states, formally notified Meridian in writing that it had decided to reduce the amount of retail shelf space allocated to DermaTrūe products by 30%, effective October 1, 2025. In its notification, Kingsley cited "declining consumer demand" for DermaTrūe products as the primary reason for the shelf-space reduction. Kingsley is one of Meridian's largest retail accounts and has been a key distribution partner for the DermaTrūe line since 2015. The shelf-space reduction at Kingsley is a direct and foreseeable consequence of Apex's false advertising campaign, which has depressed consumer demand for DermaTrūe products by creating false perceptions of overpricing and inferior efficacy.

50. Meridian estimates the annual revenue impact of the Kingsley shelf-space reduction at approximately $4.1 million. However, the harm extends far beyond the immediate revenue impact. Retail shelf space is among the most critical competitive assets in the consumer products industry. Shelf-space allocation decisions are difficult to reverse once made, as retailers are reluctant to reallocate space that has been given to competing products. The loss of prominent shelf space at a major national chain also has cascading effects on consumer visibility, impulse purchasing, and brand perception — consumers who no longer see DermaTrūe products prominently displayed at their local drugstore may infer that the brand is declining in popularity or quality. Moreover, upon information and belief, the Kingsley shelf-space reduction may prompt similar decisions by other retail partners, creating a domino effect that would compound the harm to Meridian's distribution network and market presence.

4. Apex's Unjust Enrichment

51. Upon information and belief, Apex has been unjustly enriched as a direct result of its false advertising campaign. During Q2 and Q3 2025 (April through September 2025), Apex realized incremental PuraClear revenue of approximately $19.8 million that is attributable to the false advertising campaign — revenue that was diverted from Meridian and other competitors through the dissemination of false and misleading claims. At PuraClear's estimated blended gross margin of approximately 56.5%, Apex earned approximately $11.2 million in incremental gross profits directly from the deceptive campaign. These profits were gained at the direct expense of Meridian and its DermaTrūe brand, and Apex should not be permitted to retain the fruits of its deceptive conduct.

52. Apex's estimated campaign spend of $23.0 million during the period of June through August 2025 further underscores the scale, deliberateness, and premeditated nature of the campaign. Apex made a calculated business decision to invest $23.0 million in disseminating claims that it knew, or should have known, were false and misleading, with the expectation that the false claims would generate returns in excess of the campaign investment by diverting sales from Meridian and other competitors. This is not a case of inadvertent error or isolated misstatement; it is a case of a well-financed, carefully orchestrated campaign of competitive deception.

CAUSES OF ACTION

COUNT I

FALSE ADVERTISING UNDER THE LANHAM ACT 15 U.S.C. § 1125(a)

53. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.

54. Defendant Apex Naturals Inc. has made, and continues to make, false and misleading descriptions of fact and false and misleading representations of fact in commercial advertising and promotion, in connection with goods placed in interstate commerce, in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).

55. Specifically, and without limitation, Apex has disseminated the following false and misleading claims in its "The PuraClear Truth" advertising campaign:

(a) Apex has falsely claimed that a "controlled clinical study" demonstrated that PuraClear reduces visible acne blemishes "47% faster" than "the leading DermaTrūe treatment," citing as its purported source a fabricated study ("Guerrero et al., 2024, Independent Dermatological Review") that was never published in any peer-reviewed journal and that does not exist. The only testing Apex conducted was a non-blinded, 22-person pilot study without a control group, which is wholly insufficient to substantiate the claim;

(b) Apex has made a materially misleading price comparison between PuraClear and DermaTrūe, claiming that "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit," when in fact the comparison pits a single 1.0 oz. PuraClear Spot Treatment tube against a 5.2 oz. DermaTrūe Complete Acne System kit containing three separate products. On a per-ounce basis, DermaTrūe is less than half the price of PuraClear, making the advertisement's claim the opposite of the truth; and

(c) Apex has falsely claimed that "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances," when in fact Meridian's reformulated DermaTrūe Pure products are also free of all parabens, sulfates, and synthetic fragrances, as independently confirmed by laboratory testing.

56. The foregoing false and misleading statements were made in "commercial advertising or promotion" within the meaning of the Lanham Act. The statements were disseminated to the general public and to potential purchasers of acne-treatment products through national television advertisements, digital video advertisements on Crowne Albany Partners LLC, Dunmore & Co., and Northpoint Services Inc. Reels, in-store point-of-sale displays at major drugstore chains, print advertisements in consumer magazines, and the dedicated campaign page on Apex's corporate website. The statements were made in interstate commerce, as they were disseminated across state lines to consumers throughout the United States.

57. Each of the false and misleading statements described above is material to consumer purchasing decisions. Claims regarding clinical efficacy, price, and ingredient safety are among the most important factors that consumers consider when choosing acne-treatment products. The false claims have the tendency to deceive, and have actually deceived, a substantial segment of the relevant consumer audience, as evidenced by the consumer-perception survey conducted by Dr. Eleanor Fisk, which demonstrated significant shifts in consumer perceptions of DermaTrūe's pricing and efficacy following exposure to the campaign.

58. Meridian has been, and continues to be, directly and proximately injured by Apex's false advertising. Meridian has suffered lost sales, lost profits, diminished brand equity, damage to its reputation for quality and value, and loss of critical retail shelf space, all as detailed above. Meridian is likely to continue to suffer such injuries absent injunctive relief from this Court. The injuries Meridian has suffered are the type of commercial injuries that Section 43(a) of the Lanham Act was designed to prevent.

59. Apex's conduct has been willful, deliberate, and undertaken in bad faith. Apex launched its $23.0 million campaign with full knowledge that its claims were false or, at a minimum, unsubstantiated. Apex refused to cease or modify the campaign following Meridian's cease-and-desist letter, refused to comply with NAD's preliminary recommendation to discontinue or modify the clinical superiority and price-comparison claims, and has continued to disseminate the false advertisements without modification through the date of filing of this Complaint. Apex's willful conduct entitles Meridian to enhanced damages and attorneys' fees under 15 U.S.C. § 1117(a).

COUNT II

DECEPTIVE ACTS AND PRACTICES NEW YORK GENERAL BUSINESS LAW § 349

60. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.

61. Apex's false and misleading "The PuraClear Truth" advertising campaign constitutes consumer-oriented conduct that is deceptive and misleading in a material way, in violation of New York General Business Law § 349. The campaign is directed at consumers at large and is designed to influence their purchasing decisions through false representations regarding the clinical efficacy, pricing, and ingredient safety of PuraClear products relative to DermaTrūe products.

62. Apex's deceptive acts and practices were directed at consumers and had a broad impact on consumers at large in the State of New York and throughout the United States. The campaign was disseminated through mass media channels — including national television, digital platforms, in-store displays at retail locations in New York, and print media distributed in New York — and was designed to reach millions of consumers, including consumers in New York who are purchasers or potential purchasers of acne-treatment products.

63. The deceptive acts and practices alleged herein are likely to mislead a reasonable consumer acting reasonably under the circumstances. The claims at issue — a purported peer-reviewed clinical study, a side-by-side price comparison, and a comparative ingredient claim — are presented in a manner that a reasonable consumer would accept at face value and that would materially influence such a consumer's purchasing decision.

64. Meridian has suffered injury as a result of Apex's deceptive practices, including but not limited to lost sales, lost profits, diminished brand equity, and loss of retail shelf space, as set forth in detail above. Pursuant to New York General Business Law § 349(h), Meridian is entitled to recover its actual damages, or fifty dollars, whichever is greater, as well as treble damages up to one thousand dollars, reasonable attorneys' fees, and costs.

COUNT III

FALSE ADVERTISING NEW YORK GENERAL BUSINESS LAW § 350

65. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.

66. Apex's "The PuraClear Truth" advertising campaign constitutes advertising that is false, misleading, and deceptive within the meaning of New York General Business Law § 350. The campaign contains representations and statements of fact that are untrue, deceptive, and misleading, including the fabricated clinical superiority claim, the misleading price comparison, and the false "clean" ingredients claim, each of which is described in detail above.

67. The false advertisements specifically target and disparage Meridian's DermaTrūe products by name through literally false claims and materially misleading comparisons. The false advertising was disseminated in New York through national television broadcasts received in New York, digital advertisements served to New York consumers, in-store displays at drugstore locations in New York, and print media distributed in New York, and through a publicly accessible campaign website.

68. Meridian has been injured by Apex's false advertising through lost sales, lost profits, diminished brand value, damage to consumer trust, and loss of retail shelf space, as set forth in detail above. Pursuant to New York General Business Law § 350-e, Meridian is entitled to recover compensatory damages, or five hundred dollars, whichever is greater, and reasonable attorneys' fees.

COUNT IV

COMMON-LAW UNFAIR COMPETITION

69. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.

70. Apex's conduct, as alleged herein, constitutes unfair competition under the common law of the State of New York. By conceiving, developing, funding, and disseminating a nationwide false and misleading comparative advertising campaign that expressly targets Meridian's DermaTrūe products by name, Apex has engaged in deceptive, dishonest, and unethical commercial practices designed to misappropriate Meridian's market share, divert Meridian's customers and revenue, and gain an unfair competitive advantage through misrepresentations of material fact. Apex's conduct goes beyond legitimate competitive activity and constitutes the type of commercial immorality that the law of unfair competition is designed to prevent.

71. Apex's conduct was undertaken in bad faith and with the deliberate intent to injure Meridian, to deceive consumers, and to misappropriate the substantial goodwill that Meridian has built in its DermaTrūe brand through years of investment in product development, marketing, and consumer trust. Apex's willingness to invest $23.0 million in a campaign built on fabricated studies, misleading price comparisons, and false ingredient claims demonstrates a calculated and premeditated scheme to advance Apex's commercial interests at Meridian's expense through dishonest means.

72. Meridian has been damaged as a direct and proximate result of Apex's unfair competitive practices, including through lost sales and profits, diminished brand equity and goodwill, damage to consumer trust, and loss of retail shelf space, all as detailed above. Meridian is entitled to recover compensatory damages, disgorgement of Apex's profits, and injunctive relief.

COUNT V

TORTIOUS INTERFERENCE WITH BUSINESS RELATIONS

73. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.

74. Meridian had existing and prospective business relationships with its retail customers and distribution partners, including but not limited to Kingsley Drug Stores LLC, a major national retail chain operating more than 2,400 stores across 42 states. Meridian's relationship with Kingsley dates back to 2015 and has been a significant and valuable component of Meridian's retail distribution network. Meridian also maintains business relationships with numerous other national and regional retailers that carry and sell DermaTrūe products, each of which constitutes a valuable business relationship that has been placed at risk by Apex's conduct.

75. Apex knew, or should have known, of Meridian's business relationships with its retail customers, including Kingsley Drug Stores LLC and other major retail chains. Meridian's retail distribution network is a matter of public knowledge in the industry, and DermaTrūe products are prominently displayed in thousands of retail locations nationwide. Moreover, Apex, as a direct competitor of Meridian in the acne-treatment market, has intimate knowledge of Meridian's retail distribution channels, as both companies compete for shelf space at many of the same retail chains.

76. Apex intentionally and improperly interfered with Meridian's business relationships with its retail customers through the deliberate dissemination of its false and misleading "The PuraClear Truth" advertising campaign. The false claims contained in the campaign caused consumers to lose confidence in DermaTrūe products, which in turn caused consumer demand for DermaTrūe products to decline, which in turn caused retailers to reduce or threaten to terminate their business with Meridian. The interference was accomplished through wrongful means — specifically, through the dissemination of false and misleading advertising that violates federal and state law — and was motivated by Apex's desire to gain an unfair competitive advantage at Meridian's expense.

77. As a direct and proximate result of Apex's tortious interference, on August 5, 2025, Kingsley Drug Stores LLC formally notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025. Kingsley cited "declining consumer demand" for DermaTrūe products as the primary reason for the shelf-space reduction — demand that declined as a direct and proximate result of Apex's false and misleading campaign.

78. Meridian estimates the annual revenue impact of the Kingsley shelf-space reduction at approximately $4.1 million. The harm extends beyond this direct revenue impact, as the shelf-space reduction diminishes DermaTrūe's retail visibility, reduces consumer access to DermaTrūe products, and may trigger similar reductions by other retail partners.

79. But for Apex's wrongful conduct, Kingsley Drug Stores LLC would not have reduced DermaTrūe shelf space, and Meridian would have continued to enjoy its prior level of business with Kingsley. Similarly, but for Apex's wrongful conduct, Meridian's business relationships with other retailers would not have been impaired, and Meridian would not have suffered the decline in consumer demand and brand perception that has damaged its retail partnerships. Meridian is entitled to recover compensatory damages for the harm caused by Apex's tortious interference.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff Meridian Consumer Brands LLC respectfully requests that this Court enter judgment in its favor and against Defendant Apex Naturals Inc. and award Plaintiff the following relief:

(a) Preliminary Injunction: Enter a preliminary injunction, pursuant to Rule 65 of the Federal Rules of Civil Procedure, ordering Defendant Apex Naturals Inc. to immediately cease all dissemination of "The PuraClear Truth" campaign materials across all media channels, including but not limited to national television, digital video platforms (Crowne Albany Partners LLC, Dunmore & Co., Northpoint Services Inc. Reels, and all other digital and social media platforms), in-store point-of-sale displays, print advertisements, and the internet; to immediately remove the campaign page located at www.apexnaturals.com/puraclear-truth and all related content from Apex's website; and to refrain from making the clinical superiority claim, the price-comparison claim, the "clean" ingredients claim, or any substantially similar claims, in any medium, pending final adjudication of this action;

(b) Permanent Injunction: Enter a permanent injunction permanently enjoining Defendant Apex Naturals Inc., and its officers, directors, employees, agents, representatives, successors, assigns, and all persons acting in concert or participation with them, from disseminating any of the false and misleading claims identified herein, or any substantially similar claims, in any medium, and from engaging in any false advertising or deceptive trade practices directed at Meridian or Meridian's products;

(c) Corrective Advertising: Order Defendant Apex Naturals Inc. to fund and disseminate corrective advertising, at Apex's sole expense, in a form, scope, duration, and through media channels to be determined by the Court, sufficient to dispel the false impressions created by "The PuraClear Truth" campaign among consumers and the trade;

(d) Compensatory Damages: Award Plaintiff Meridian Consumer Brands LLC compensatory damages for lost profits and other economic losses caused by Defendant's false advertising, in an amount to be proven at trial, preliminarily estimated at $18.5 million on an annualized basis;

(e) Disgorgement of Profits: Award Plaintiff Meridian Consumer Brands LLC disgorgement of Defendant Apex Naturals Inc.'s profits attributable to the false advertising campaign, in an amount to be proven at trial, preliminarily estimated at $11.2 million, based on estimated incremental PuraClear revenue of $19.8 million at an estimated gross margin of 56.5%;

(f) Treble Damages: Award treble damages pursuant to 15 U.S.C. § 1117(a) in light of Defendant's willful and deliberate conduct, in an amount up to $55.5 million ($18.5 million × 3), or such greater amount as may be proven at trial;

(g) Attorneys' Fees and Costs: Award Plaintiff Meridian Consumer Brands LLC its reasonable attorneys' fees and costs of suit incurred in connection with this action, pursuant to 15 U.S.C. § 1117(a) and applicable provisions of New York law, this being an exceptional case warranting such an award;

(h) Prejudgment and Post-Judgment Interest: Award Plaintiff Meridian Consumer Brands LLC prejudgment interest from the date of the first actionable wrong and post-judgment interest from the date of judgment, at the highest rates permitted by applicable law; and

(i) Other Relief: Grant such other and further relief as this Court deems just, equitable, and proper.

DEMAND FOR JURY TRIAL

Plaintiff Meridian Consumer Brands LLC hereby demands a trial by jury on all claims and issues so triable in this action, pursuant to Rule 38 of the Federal Rules of Civil Procedure and the Seventh Amendment to the United States Constitution.

VERIFICATION

I, Derek Cho, declare and state as follows:

1. I am the General Counsel of Meridian Consumer Brands LLC, the Plaintiff in this action. I am authorized to make this verification on behalf of Meridian Consumer Brands LLC.

2. I have read the foregoing Verified Complaint for Injunctive Relief, Damages, and Other Relief. The factual allegations contained therein are true and correct to the best of my knowledge, information, and be

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK
VERIFIED COMPLAINT FOR INJUNCTIVE RELIEF, DAMAGES, AND OTHER RELIEF
Matter No. 1011-00004
TABLE OF CONTENTS
Right-click to update Table of Contents
INTRODUCTION
1. This is an action for false advertising, deceptive business practices, unfair competition, and tortious interference with business relations brought by Plaintiff Meridian Consumer Brands LLC ("Meridian" or "Plaintiff") against Defendant Apex Naturals Inc. ("Apex" or "Defendant") arising from Apex's nationwide comparative advertising campaign known as "The PuraClear Truth," which Apex launched on or about June 2, 2025. Meridian brings this action to halt Apex's ongoing campaign of deception, to obtain redress for the substantial injuries Meridian has already suffered, and to prevent further irreparable harm to Meridian's brand, business, and consumer relationships.
2. Beginning on or about June 2, 2025, Apex launched a multi-channel comparative advertising campaign under the name "The PuraClear Truth," which has been disseminated across national television (including 30-second and 60-second commercial spots airing during prime-time and daytime programming), digital video platforms (including Crowne Albany Partners LLC, Dunmore & Co., and Northpoint Services Inc. Reels), in-store point-of-sale displays at major drugstore chains throughout the United States, print advertisements placed in widely circulated consumer magazines, and a dedicated campaign page hosted on Apex's corporate website at www.apexnaturals.com/puraclear-truth. Upon information and belief, Apex's total estimated media spend for the campaign during the period of June through August 2025 was approximately $23.0 million, comprising approximately $14.3 million in national television advertising expenditures and approximately $8.7 million in digital and social media advertising expenditures. The scope, reach, and intensity of this campaign underscore the deliberateness of Apex's scheme and the magnitude of the harm it has inflicted and continues to inflict upon Meridian.
3. The campaign makes three categories of materially false and misleading claims about Apex's "PuraClear" acne-treatment product line relative to Meridian's flagship "DermaTrūe" product family. First, the campaign asserts a fabricated clinical superiority claim, purportedly based on a peer-reviewed study that does not exist, stating that PuraClear reduces visible acne blemishes "47% faster" than DermaTrūe. Second, the campaign features a deliberately misleading apples-to-oranges price comparison that juxtaposes the price of a single 1.0 oz. PuraClear tube against the price of a multi-product, 5.2 oz. DermaTrūe regimen kit, creating the false impression that DermaTrūe is overpriced when, in fact, DermaTrūe is significantly less expensive on a per-ounce basis. Third, the campaign falsely claims that DermaTrūe products contain parabens, sulfates, and synthetic fragrances, when Meridian's reformulated DermaTrūe Pure products are entirely free of all such ingredients — a fact independently verified by a third-party laboratory. Each of these categories of false claims is designed to deceive consumers and divert sales from Meridian to Apex.
4. As a direct and proximate result of Apex's false and deceptive campaign, Meridian has suffered — and continues to suffer — substantial and ongoing harm. DermaTrūe revenue declined from $36.8 million in the third quarter of fiscal year 2024 to $29.4 million in the third quarter of fiscal year 2025, representing a year-over-year decline of $7.4 million, or 20.1%. Consumer survey data demonstrates severe brand-perception damage: the percentage of consumers who perceive DermaTrūe as "overpriced" increased by 23 percentage points following the launch of the campaign, and the percentage who believe DermaTrūe is "less effective" than PuraClear increased by 19 percentage points. Moreover, on August 5, 2025, Kingsley Drug Stores LLC ("Kingsley"), a major national drugstore chain operating more than 2,400 retail locations, notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025, citing declining consumer demand — demand that declined as a direct result of Apex's false advertising. The damage to Meridian's brand reputation, retail relationships, and consumer trust is ongoing, is escalating, and cannot be fully remedied through monetary damages alone.
5. By this Complaint, Meridian brings claims under Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a); New York General Business Law §§ 349 and 350; and the common law of the State of New York, including claims for unfair competition and tortious interference with business relations. Meridian seeks preliminary and permanent injunctive relief ordering Apex to immediately and permanently cease its false advertising campaign; compensatory damages for Meridian's lost profits; disgorgement of Apex's ill-gotten profits attributable to the false advertising; treble damages in light of Apex's willful conduct; an order requiring Apex to fund and disseminate corrective advertising sufficient to dispel the false impressions created by the campaign; and an award of Meridian's reasonable attorneys' fees and costs.
PARTIES
A. Plaintiff Meridian Consumer Brands LLC
6. Plaintiff Meridian Consumer Brands LLC is a limited liability company duly organized and existing under the laws of the State of Delaware and registered to do business in the State of New York. Meridian maintains its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001.
7. Meridian is principally engaged in the development, marketing, and retail distribution of premium skincare, personal-care, and over-the-counter dermatological products throughout the United States and in select international markets. Meridian's portfolio of consumer brands includes DermaTrūe, a leading acne and blemish treatment line; Velara, an anti-aging skincare collection; and SkinSense, a line of products formulated for sensitive skin. Meridian's products are sold through major national and regional retail chains, specialty beauty retailers, and e-commerce platforms, and are available in thousands of retail locations across the country.
8. For the fiscal year ending December 31, 2024, Meridian's total annual revenue was approximately $487.6 million, as reported in Meridian's audited financial statements prepared by Ashford & Kline LLP, Certified Public Accountants. The DermaTrūe product line is Meridian's largest individual brand by revenue, having generated approximately $138.2 million in revenue during fiscal year 2024, representing approximately 28.3% of Meridian's total revenue. The DermaTrūe brand is a cornerstone of Meridian's business and represents years of investment in product development, clinical testing, brand building, and consumer trust.
9. Meridian is a portfolio company of Brindoval Capital Partners Fund IV LP, a Delaware limited partnership, which acquired Meridian in 2019. Since Brindoval's acquisition, Meridian has invested significantly in product innovation, brand development, and market expansion, including the 2024 reformulation and relaunch of the DermaTrūe line as "DermaTrūe Pure."
10. Meridian's senior leadership includes Nathan Hartwell, Chief Executive Officer; Julia Whitmore, Chief Marketing Officer; Derek Cho, General Counsel; and Dr. Annika Patel, Vice President, Regulatory and Scientific Affairs. Each of these individuals has personal knowledge of the facts alleged in this Complaint.
B. Defendant Apex Naturals Inc.
11. Defendant Apex Naturals Inc. is a corporation duly organized and existing under the laws of the State of Delaware, with its principal place of business at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex's registered agent for service of process in Delaware is Pinnacle Registered Agents LLC, located at 1209 Orange Street, Wilmington, Delaware 19801. Upon information and belief, Apex is authorized to transact business in the State of New York and regularly does so.
12. Apex is principally engaged in the development, manufacturing, marketing, and sale of mass-market and "clean-beauty" skincare and acne-treatment products, which are sold primarily through national drugstore chains, mass-market retail outlets, and e-commerce channels, including Apex's own direct-to-consumer website. Apex's portfolio of consumer brands includes PuraClear, an acne treatment line that directly competes with Meridian's DermaTrūe products; GreenVeil, a line of moisturizers; and ClearPath, a line of body wash products. PuraClear is Apex's largest individual brand and its primary competitive offering in the acne-treatment category.
13. Upon information and belief, Apex's estimated total annual revenue for the fiscal year ending December 31, 2024, was approximately $312.4 million. The PuraClear product line generated an estimated $89.7 million in revenue during fiscal year 2024, representing approximately 28.7% of Apex's total revenue. DermaTrūe and PuraClear are direct competitors in the acne-treatment market, competing for the same consumers, the same retail shelf space, and the same market share.
14. Apex's senior leadership includes Marcus Devlin, Founder and Chief Executive Officer; Rachel Emory, Chief Marketing Officer; Dr. Simon Guerrero, Vice President, Product Development; and Tanya Fischetti, General Counsel. Upon information and belief, Mr. Devlin, Ms. Emory, and Dr. Guerrero were each personally involved in the development, approval, and dissemination of "The PuraClear Truth" campaign that is the subject of this Complaint.
JURISDICTION AND VENUE
15. Subject Matter Jurisdiction — Federal Question. This Court has original subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1331 because this action arises under the laws of the United States, specifically Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a), which provides a federal cause of action for false advertising and unfair competition in interstate commerce. The amount in controversy exceeds $75,000, exclusive of interest and costs.
16. Supplemental Jurisdiction. This Court has supplemental jurisdiction over Plaintiff's state-law claims — including claims under New York General Business Law §§ 349 and 350, and Plaintiff's common-law claims for unfair competition and tortious interference with business relations — pursuant to 28 U.S.C. § 1367(a), because those claims are so related to the federal Lanham Act claim as to form part of the same case or controversy under Article III of the United States Constitution. The state-law claims arise from the same nucleus of operative fact as the federal claim, namely, Apex's nationwide false advertising campaign targeting Meridian's DermaTrūe products.
17. Personal Jurisdiction. Defendant Apex Naturals Inc. is subject to personal jurisdiction in this judicial district. Apex has purposefully directed its advertising campaign — including the false and misleading "The PuraClear Truth" campaign — at consumers throughout the State of New York. National television advertisements containing the false claims have been broadcast to and received by consumers in this district. Digital advertisements have been served to and viewed by consumers in this district through Crowne Albany Partners LLC, Dunmore & Co., Northpoint Services Inc. Reels, and other online platforms. In-store point-of-sale displays featuring the false claims have been placed in drugstore locations throughout the State of New York, including in this district. Print advertisements have been distributed in consumer magazines circulated in this district. The campaign page on Apex's website at www.apexnaturals.com/puraclear-truth is accessible to and has been accessed by consumers in this district. Moreover, upon information and belief, Apex regularly conducts business in New York, ships products to retailers and consumers in New York, and derives substantial revenue from sales in New York. Apex's contacts with this forum are sufficient to establish both general and specific personal jurisdiction under New York's long-arm statute, N.Y. C.P.L.R. § 302(a), and are consistent with the requirements of the Due Process Clause of the Fourteenth Amendment.
18. Venue. Venue is proper in this judicial district pursuant to 28 U.S.C. § 1391(b)(2) because a substantial part of the events or omissions giving rise to the claims asserted herein occurred in this district. The false advertisements at issue have been disseminated to, received by, and have impacted consumers and retailers in this district. Plaintiff Meridian maintains its principal place of business in this district, and the harm to Meridian's business, brand reputation, and retail relationships has been felt acutely in this district. Venue is also proper under 28 U.S.C. § 1391(b)(1) because Apex is subject to personal jurisdiction in this district.
FACTUAL ALLEGATIONS
A. Meridian's DermaTrūe Product Line
19. Meridian has developed, manufactured, and marketed the DermaTrūe product family since 2011, when the line was first introduced to the market as a premium acne and blemish treatment system. Over the past fourteen years, Meridian has invested tens of millions of dollars in research and development, clinical testing, regulatory compliance, brand building, and marketing to establish DermaTrūe as one of the leading acne-treatment brands in the United States. The current DermaTrūe product line includes a range of products formulated to address various types and severities of acne. The flagship product offering is the DermaTrūe Complete Acne System, a three-piece regimen kit containing a 2.0 oz. facial cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer, for a combined total of 5.2 oz. of product. The DermaTrūe Complete Acne System retails at a manufacturer's suggested retail price ("MSRP") of $28.99, which equates to a per-ounce price of approximately $5.57. The DermaTrūe line also includes individual products such as DermaTrūe Daily Cleanser, DermaTrūe Intensive Treatment Gel, DermaTrūe Oil-Free Moisturizer, and DermaTrūe Overnight Repair Serum, all of which are competitively priced within the premium acne-treatment segment.
20. In 2024, Meridian undertook a comprehensive reformulation and relaunch of the DermaTrūe product line under the name "DermaTrūe Pure." The reformulation was driven by consumer demand for "clean-beauty" products and involved the removal of all parabens, sulfates, and synthetic fragrances from every product in the DermaTrūe line, while maintaining the same clinically validated active-ingredient profiles and efficacy standards. Meridian invested approximately $6.2 million in the reformulation process, including ingredient sourcing, stability testing, consumer trials, and regulatory review. The reformulated ingredient profile of every DermaTrūe Pure product was independently tested and confirmed by Beacon Scientific Laboratories LLC ("Beacon Scientific"), an accredited independent testing laboratory, in Lab Report No. BSL-2025-0412, dated March 15, 2025. Beacon Scientific's testing confirmed that the DermaTrūe Pure products are free of all parabens (including methylparaben, ethylparaben, propylparaben, butylparaben, and isobutylparaben), free of all sulfates (including sodium lauryl sulfate and sodium laureth sulfate), and free of all synthetic fragrances. The DermaTrūe Pure product line has been on the market and available at retail since April 2024.
21. The DermaTrūe line is a cornerstone of Meridian's business and its single largest source of revenue. In fiscal year 2024, the DermaTrūe product line generated approximately $138.2 million in revenue, representing approximately 28.3% of Meridian's total revenue of $487.6 million. DermaTrūe products carry a blended gross margin of approximately 62.5%, reflecting the premium positioning, high-quality ingredients, and strong consumer demand for the brand. DermaTrūe is Meridian's most profitable product line and a critical driver of the company's overall financial performance.
22. Meridian has invested substantial time, resources, and capital in building the DermaTrūe brand's reputation among consumers, dermatologists, and retail partners for quality, efficacy, safety, and value. Meridian has spent an average of approximately $22 million per year over the past five years on DermaTrūe-related advertising, marketing, and promotional activities, including national television advertising, digital marketing, influencer partnerships, point-of-sale materials, and trade marketing programs with retail partners. As a result of these sustained investments, DermaTrūe has achieved strong brand recognition, consumer loyalty, and retailer confidence, all of which constitute valuable goodwill that Apex's false advertising campaign has damaged and continues to damage.
B. Apex's "The PuraClear Truth" Campaign
23. On or about June 2, 2025, Defendant Apex Naturals Inc. launched a nationwide comparative advertising campaign under the name "The PuraClear Truth." Upon information and belief, the campaign was referred to internally at Apex as "Project Clarity." The campaign was conceived, developed, and produced by Brightline Creative Partners LLC ("Brightline"), an advertising agency headquartered at 55 Washington Street, Suite 900, Brooklyn, New York 11201, under the creative direction of Owen Prescott, Brightline's Chief Creative Officer. Upon information and belief, the campaign strategy was approved at the highest levels of Apex's management, including by Marcus Devlin, Apex's CEO and Founder; Rachel Emory, Apex's CMO; and Dr. Simon Guerrero, Apex's VP of Product Development.
24. "The PuraClear Truth" campaign has been disseminated broadly across multiple media channels, ensuring maximum reach among the target consumer audience for acne-treatment products. The campaign includes 30-second and 60-second television commercial spots that have aired on national broadcast and cable networks during prime-time, daytime, and weekend programming blocks. The campaign also includes digital video advertisements distributed through Crowne Albany Partners LLC (both pre-roll and mid-roll placements), Dunmore & Co. (sponsored content and in-feed advertisements), and Northpoint Services Inc. Reels (sponsored placements and story advertisements). In addition, Apex has distributed in-store point-of-sale displays — including shelf talkers, end-cap displays, and countertop displays — at major drugstore chains throughout the United States, including at retail locations in the State of New York and in this judicial district. The campaign further includes print advertisements placed in widely circulated consumer magazines, including publications focused on health, beauty, and lifestyle. Finally, Apex has maintained a dedicated campaign page on its corporate website at www.apexnaturals.com/puraclear-truth, which consolidates the campaign's messaging, video content, and claims in a single, publicly accessible location.
25. Upon information and belief, the estimated total media spend for "The PuraClear Truth" campaign during the period of June through August 2025 was approximately $23.0 million. Of this total, approximately $14.3 million was allocated to national television advertising placements, and approximately $8.7 million was allocated to digital and social media advertising placements. The scale of this media investment reflects a deliberate and aggressive strategy to saturate the market with the campaign's false claims, maximize consumer exposure to those claims, and inflict maximum competitive damage on Meridian's DermaTrūe brand.
26. The campaign expressly and prominently names and targets Meridian's DermaTrūe product line by name. Throughout the campaign materials — including television spots, digital videos, in-store displays, print advertisements, and the campaign website — DermaTrūe is identified by name and used as a point of comparison to promote PuraClear's purported advantages. The campaign does not merely make general claims about PuraClear; it specifically and repeatedly attacks DermaTrūe's efficacy, pricing, and ingredient profile through false and misleading comparative claims. The targeting of DermaTrūe by name was a deliberate strategic decision designed to divert DermaTrūe's loyal customer base to PuraClear.
C. The False Clinical Superiority Claim
27. A central and prominently featured claim in "The PuraClear Truth" campaign is a purported clinical superiority claim. The campaign prominently states, across television spots, digital advertisements, in-store displays, and the campaign website: "In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment." The advertisement further cites the purported source study as "Guerrero et al., 2024, Independent Dermatological Review." This citation appears on-screen during television and digital video advertisements as a superimposed text citation, is printed in fine print on in-store point-of-sale displays, and is included in a footnote on the campaign website. The citation is formatted and presented in the style of a legitimate academic journal citation, and is designed to convey to consumers the impression that the 47% superiority claim is supported by an independent, rigorous, peer-reviewed scientific study.
28. Upon information and belief, no study authored by "Guerrero et al." was published in 2024 — or at any other time — in any peer-reviewed journal. Upon further information and belief, no journal titled Independent Dermatological Review exists as a recognized peer-reviewed dermatological or scientific publication. A thorough search of major academic databases, including PubMed, Hollowell Data Systems, Web of Science, and the National Library of Medicine catalog, has revealed no record of any journal bearing that title, and no record of any published study matching the cited authorship, date, or findings. The citation is fabricated.
29. Upon information and belief, the only testing that Apex conducted or caused to be conducted in connection with any comparison between PuraClear and DermaTrūe products was a non-blinded, 22-person pilot study that lacked a placebo control group, was not randomized, and did not employ any of the methodological safeguards — including blinding, randomization, adequate sample size, and statistical controls — that are necessary to satisfy generally accepted standards for clinical research design in dermatology. A 22-person pilot study without a control group does not and cannot substantiate the claim that PuraClear reduces acne blemishes "47% faster" than DermaTrūe or any other specific competitive product. The results of such a study are not statistically significant, are not generalizable, and do not constitute competent and reliable scientific evidence.
30. It is notable and telling that Dr. Simon Guerrero — Apex's own Vice President of Product Development — is the named lead author on the purported study cited in the campaign. Dr. Guerrero is a salaried employee of Apex with a direct financial interest in the success of the PuraClear brand. The fact that the purported study's lead author is an Apex executive further underscores that the study was neither independent nor published in any legitimate peer-reviewed journal, notwithstanding the campaign's deliberate use of the word "Independent" in the title of the fabricated journal to create a false impression of objectivity.
31. The clinical superiority claim contained in "The PuraClear Truth" campaign — that "PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment" — is literally false. It purports to be based on a published, peer-reviewed clinical study that does not exist. Alternatively, and at a minimum, the claim is misleading to a substantial portion of the relevant consumer audience because it creates the false impression that PuraClear's superiority over DermaTrūe has been scientifically established through rigorous, independent clinical research, when in fact no competent and reliable scientific evidence supports the claim. In either case, the claim is materially deceptive and is the type of claim that has the tendency to influence consumers' purchasing decisions.
D. The False Price Comparison Claim
32. Another prominent claim in "The PuraClear Truth" campaign is a comparative price claim. The campaign states, across television spots, digital advertisements, in-store displays, and the campaign website: "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit." This claim is presented with visual side-by-side comparisons of the two products, with the PuraClear product displayed alongside a price of "$12.99" and the DermaTrūe product displayed alongside a price of "$28.99," creating a stark and visually compelling — but fundamentally misleading — impression of a dramatic price disparity.
33. This price comparison is materially misleading because it compares non-comparable products of vastly different sizes, compositions, and intended uses. The PuraClear product cited at $12.99 is a single 1.0 oz. tube of PuraClear Spot Treatment — a single-purpose product designed for targeted application to individual blemishes. The DermaTrūe product cited at $28.99 is the DermaTrūe Complete Acne System — a comprehensive three-piece regimen kit containing a 2.0 oz. cleanser, a 1.5 oz. treatment gel, and a 1.7 oz. moisturizer, for a combined total of 5.2 oz. of product. The DermaTrūe Complete Acne System includes three distinct products designed to be used together as part of a comprehensive daily skincare regimen, while the PuraClear Spot Treatment is a single product with a single function. The two products are not "comparable" in any meaningful sense — not in size, not in composition, not in functionality, and not in the scope of treatment they provide.
34. On a per-ounce basis — the standard and accepted metric for comparing the prices of consumer products of different sizes — the DermaTrūe Complete Acne System costs approximately $5.57 per ounce ($28.99 ÷ 5.2 oz.), while the PuraClear Spot Treatment costs $12.99 per ounce ($12.99 ÷ 1.0 oz.). The PuraClear product is thus more than double the price of the DermaTrūe product on a per-ounce basis — more than 2.3 times the per-ounce cost. The campaign's claim that PuraClear is available at "half the price" of a "comparable" DermaTrūe product is not merely misleading; it is the precise opposite of the truth when measured on any fair, industry-standard unit-price basis. The price comparison turns reality on its head, portraying the less expensive product (DermaTrūe, on a per-ounce basis) as the more expensive one, and vice versa.
35. The campaign deliberately and knowingly exploits the difference between the absolute retail price of a multi-product regimen kit and the absolute retail price of a single small tube to manufacture the false impression that DermaTrūe products are overpriced relative to PuraClear. This is a classic and well-recognized form of misleading price comparison — comparing a large format or bundled product to a small, single-unit product — and Apex employs it here with full knowledge that the comparison is unfair, misleading, and designed to deceive consumers. The false price comparison is particularly harmful because price sensitivity is a major driver of consumer purchasing decisions in the acne-treatment category, and the false impression that DermaTrūe is overpriced directly undermines Meridian's competitive position and brand equity.
E. The False "Clean" Ingredients Claim
36. The third category of false claims in "The PuraClear Truth" campaign involves a comparative "clean" ingredients claim. The campaign states, across television spots, digital advertisements, in-store displays, and the campaign website: "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances." The use of the word "Unlike" is specifically intended to communicate to consumers that DermaTrūe products do contain parabens, sulfates, and/or synthetic fragrances — ingredients that have been the subject of significant consumer concern and negative media coverage in recent years. The claim is designed to exploit consumer anxiety about these ingredients and to position PuraClear as a safer, cleaner alternative to DermaTrūe.
37. This claim is false. As set forth above, Meridian reformulated and relaunched the DermaTrūe product line in 2024 as "DermaTrūe Pure," and every product in the current DermaTrūe Pure line is free of parabens, free of sulfates, and free of synthetic fragrances. This has been independently confirmed by Beacon Scientific Laboratories LLC, an accredited independent testing laboratory, in Lab Report No. BSL-2025-0412, dated March 15, 2025. Beacon Scientific conducted comprehensive ingredient testing of representative samples from every product in the DermaTrūe Pure line and confirmed the absence of all parabens (including methylparaben, ethylparaben, propylparaben, butylparaben, and isobutylparaben), all sulfates (including sodium lauryl sulfate and sodium laureth sulfate), and all synthetic fragrances. The DermaTrūe Pure reformulation has been on the market for over a year, and the ingredient lists for all DermaTrūe Pure products — which are printed on the product packaging and publicly available — clearly reflect the absence of these ingredients.
38. Apex's claim that DermaTrūe contains parabens, sulfates, and/or synthetic fragrances — and that PuraClear is superior or unique in being free of these ingredients — is literally false. There is no factual basis for the claim, and Apex either knew or should have known that the claim was false at the time it launched the campaign. A simple review of DermaTrūe Pure's publicly available ingredient lists, or a basic inquiry directed to Meridian, would have revealed that the claim was untrue. The false "clean" ingredients claim misleadingly implies that consumers choosing DermaTrūe are exposing their skin to ingredients — specifically parabens, sulfates, and synthetic fragrances — that have been the subject of widespread consumer safety concerns and negative publicity. This false implication is particularly damaging because it strikes at the heart of Meridian's significant investment in reformulating its product line to meet consumer demand for clean-beauty products, and because ingredient safety is a deeply important and emotionally charged issue for consumers in the skincare market.
F. Pre-Litigation Efforts
39. Meridian has made extensive efforts to resolve this dispute prior to filing this action. On June 18, 2025 — just sixteen days after the launch of "The PuraClear Truth" campaign — Meridian's General Counsel, Derek Cho, sent a detailed cease-and-desist letter to Apex's General Counsel, Tanya Fischetti, via certified mail and email. The letter identified each of the three categories of false claims, provided supporting evidence that the claims were false, and demanded that Apex immediately withdraw all "The PuraClear Truth" advertisements across all media channels, issue a public retraction of the false claims, and confirm in writing its commitment not to repeat the false claims in the future. The letter set a response deadline of July 2, 2025.
40. On July 3, 2025 — one day after the stated deadline — Apex responded through its outside counsel, Harrison Briggs of Caldwell, Briggs & Nolan LLP, 200 Park Avenue, 42nd Floor, New York, New York 10166. In its response, Apex categorically denied all of the allegations set forth in Meridian's cease-and-desist letter. Apex asserted, without providing any supporting documentation, that all claims in "The PuraClear Truth" campaign are "truthful, substantiated, and protected by the First Amendment." Apex refused to withdraw, modify, or retract any aspect of the campaign and stated that it intended to continue the campaign as planned. At no point during the exchange did Apex produce the purported "Guerrero et al., 2024" study or any other documentation substantiating its clinical superiority claim.
41. Having failed to resolve the matter through direct communication with Apex, Meridian pursued self-regulatory relief. On July 22, 2025, Meridian filed a formal complaint with the National Advertising Division ("NAD") of the Better Business Bureau's National Programs, challenging the clinical superiority claim, the price-comparison claim, and the "clean" ingredients claim. The NAD proceeding was assigned Case Reference No. NAD-2025-01847.
42. On August 15, 2025, following an expedited review, NAD issued a preliminary recommendation that Apex discontinue or substantially modify both the clinical superiority claim and the price-comparison claim pending further substantiation. Specifically, NAD found that Apex had failed to provide adequate substantiation for the claim that PuraClear reduces visible acne blemishes "47% faster" than DermaTrūe, and that the price comparison between a 1.0 oz. single product and a 5.2 oz. multi-product kit was misleading and lacked adequate context to prevent consumer confusion. NAD deferred its recommendation on the "clean" ingredients claim pending additional information.
43. Rather than comply with the NAD's recommendation, Apex publicly stated on August 18, 2025, through a press release issued on its corporate website, that it would appeal the NAD recommendation and that it "stands behind the accuracy and integrity of 'The PuraClear Truth' campaign." Apex declined to modify any aspect of the campaign. As of the date of filing of this Complaint, Apex has continued to disseminate "The PuraClear Truth" advertisements without modification across all media channels, including national television, digital platforms, in-store displays, print media, and the campaign website. Apex's refusal to comply with the NAD's preliminary recommendation confirms that self-regulatory mechanisms are insufficient to address the ongoing harm caused by Apex's false advertising, and that judicial intervention is necessary.
G. Harm to Meridian
1. Revenue Decline
44. As a direct and proximate result of Apex's false advertising campaign, DermaTrūe revenue has declined sharply. In the third quarter of fiscal year 2024 (July through September 2024) — the last full quarter before the launch of "The PuraClear Truth" campaign — DermaTrūe generated revenue of approximately $36.8 million. In the third quarter of fiscal year 2025 (July through September 2025) — the first full quarter following the launch of the campaign — DermaTrūe revenue declined to approximately $29.4 million. This represents a year-over-year revenue decline of approximately $7.4 million, or 20.1%. This precipitous decline occurred during what should have been a period of stable or growing revenue, given the strong performance of the DermaTrūe line in prior periods, the successful relaunch of DermaTrūe Pure, and the absence of any other material changes in the competitive landscape that would account for such a severe decline.
45. At DermaTrūe's blended gross margin of approximately 62.5%, the Q3 2025 revenue decline of $7.4 million translates to lost gross profit of approximately $4.625 million for the quarter. If Apex's false advertising campaign is permitted to continue unchecked, Meridian's annualized lost gross profit attributable to the campaign is conservatively estimated at approximately $18.5 million ($4.625 million × 4 quarters). This estimate is conservative because it does not account for the compounding effects of continued brand-perception damage, additional potential retail shelf-space reductions, or the erosion of consumer loyalty that is likely to accelerate over time as the false claims continue to be disseminated.
2. Brand-Perception Damage
46. In order to quantify the impact of Apex's false advertising on consumer perceptions of the DermaTrūe brand, Meridian retained Dr. Eleanor Fisk of Fisk Analytics Group LLC, an independent consumer-research and market-analytics firm located at 101 Federal Street, Suite 2600, Boston, Massachusetts 02110, to conduct a consumer-perception survey. Dr. Fisk is a recognized expert in consumer survey research methodology and has served as a survey expert in numerous false-advertising and trademark litigation matters. The post-campaign survey was designed and fielded on August 22, 2025, using a nationally representative sample of 1,500 adults aged 18 and older, with oversampling of consumers who had purchased acne-treatment products within the prior twelve months. The survey had a margin of error of ±2.5 percentage points at the 95% confidence level.
47. Dr. Fisk's post-campaign survey produced striking and deeply concerning results. Among respondents who recalled seeing or hearing "The PuraClear Truth" advertisements, 34% agreed with the statement that DermaTrūe products are "overpriced," compared to only 11% of respondents in a baseline survey conducted by Dr. Fisk in January 2025 — before the launch of Apex's campaign. This represents a 23-percentage-point increase in the proportion of consumers who perceive DermaTrūe as overpriced, an increase that is directly attributable to Apex's false price-comparison claim. Additionally, among respondents who recalled the advertisements, 27% agreed with the statement that DermaTrūe is "less effective than PuraClear," compared to only 8% in the January 2025 baseline survey — a 19-percentage-point increase that is directly attributable to Apex's fabricated clinical superiority claim. These shifts in consumer perception are statistically significant, substantively dramatic, and highly damaging to Meridian's brand.
48. The survey results demonstrate that Apex's false claims have materially and measurably altered consumer perceptions of DermaTrūe in ways that are profoundly harmful to Meridian. Consumer perceptions of product efficacy and value are among the most important drivers of purchasing decisions in the skincare market, and the false impressions created by Apex's campaign are difficult or impossible to reverse through monetary damages alone. Even if Apex were to immediately cease the campaign, the false impressions that DermaTrūe is overpriced and less effective than PuraClear have already been planted in the minds of millions of consumers and will continue to suppress DermaTrūe sales for an extended period. This ongoing and potentially irreversible harm to Meridian's brand equity underscores the urgent need for injunctive relief, including corrective advertising.
3. Retail Shelf-Space Loss
49. On August 5, 2025, Kingsley Drug Stores LLC ("Kingsley"), a major national retail chain operating more than 2,400 stores across 42 states, formally notified Meridian in writing that it had decided to reduce the amount of retail shelf space allocated to DermaTrūe products by 30%, effective October 1, 2025. In its notification, Kingsley cited "declining consumer demand" for DermaTrūe products as the primary reason for the shelf-space reduction. Kingsley is one of Meridian's largest retail accounts and has been a key distribution partner for the DermaTrūe line since 2015. The shelf-space reduction at Kingsley is a direct and foreseeable consequence of Apex's false advertising campaign, which has depressed consumer demand for DermaTrūe products by creating false perceptions of overpricing and inferior efficacy.
50. Meridian estimates the annual revenue impact of the Kingsley shelf-space reduction at approximately $4.1 million. However, the harm extends far beyond the immediate revenue impact. Retail shelf space is among the most critical competitive assets in the consumer products industry. Shelf-space allocation decisions are difficult to reverse once made, as retailers are reluctant to reallocate space that has been given to competing products. The loss of prominent shelf space at a major national chain also has cascading effects on consumer visibility, impulse purchasing, and brand perception — consumers who no longer see DermaTrūe products prominently displayed at their local drugstore may infer that the brand is declining in popularity or quality. Moreover, upon information and belief, the Kingsley shelf-space reduction may prompt similar decisions by other retail partners, creating a domino effect that would compound the harm to Meridian's distribution network and market presence.
4. Apex's Unjust Enrichment
51. Upon information and belief, Apex has been unjustly enriched as a direct result of its false advertising campaign. During Q2 and Q3 2025 (April through September 2025), Apex realized incremental PuraClear revenue of approximately $19.8 million that is attributable to the false advertising campaign — revenue that was diverted from Meridian and other competitors through the dissemination of false and misleading claims. At PuraClear's estimated blended gross margin of approximately 56.5%, Apex earned approximately $11.2 million in incremental gross profits directly from the deceptive campaign. These profits were gained at the direct expense of Meridian and its DermaTrūe brand, and Apex should not be permitted to retain the fruits of its deceptive conduct.
52. Apex's estimated campaign spend of $23.0 million during the period of June through August 2025 further underscores the scale, deliberateness, and premeditated nature of the campaign. Apex made a calculated business decision to invest $23.0 million in disseminating claims that it knew, or should have known, were false and misleading, with the expectation that the false claims would generate returns in excess of the campaign investment by diverting sales from Meridian and other competitors. This is not a case of inadvertent error or isolated misstatement; it is a case of a well-financed, carefully orchestrated campaign of competitive deception.
CAUSES OF ACTION
COUNT I
FALSE ADVERTISING UNDER THE LANHAM ACT 15 U.S.C. § 1125(a)
53. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.
54. Defendant Apex Naturals Inc. has made, and continues to make, false and misleading descriptions of fact and false and misleading representations of fact in commercial advertising and promotion, in connection with goods placed in interstate commerce, in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).
55. Specifically, and without limitation, Apex has disseminated the following false and misleading claims in its "The PuraClear Truth" advertising campaign:
(a) Apex has falsely claimed that a "controlled clinical study" demonstrated that PuraClear reduces visible acne blemishes "47% faster" than "the leading DermaTrūe treatment," citing as its purported source a fabricated study ("Guerrero et al., 2024, Independent Dermatological Review") that was never published in any peer-reviewed journal and that does not exist. The only testing Apex conducted was a non-blinded, 22-person pilot study without a control group, which is wholly insufficient to substantiate the claim;
(b) Apex has made a materially misleading price comparison between PuraClear and DermaTrūe, claiming that "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit," when in fact the comparison pits a single 1.0 oz. PuraClear Spot Treatment tube against a 5.2 oz. DermaTrūe Complete Acne System kit containing three separate products. On a per-ounce basis, DermaTrūe is less than half the price of PuraClear, making the advertisement's claim the opposite of the truth; and
(c) Apex has falsely claimed that "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances," when in fact Meridian's reformulated DermaTrūe Pure products are also free of all parabens, sulfates, and synthetic fragrances, as independently confirmed by laboratory testing.
56. The foregoing false and misleading statements were made in "commercial advertising or promotion" within the meaning of the Lanham Act. The statements were disseminated to the general public and to potential purchasers of acne-treatment products through national television advertisements, digital video advertisements on Crowne Albany Partners LLC, Dunmore & Co., and Northpoint Services Inc. Reels, in-store point-of-sale displays at major drugstore chains, print advertisements in consumer magazines, and the dedicated campaign page on Apex's corporate website. The statements were made in interstate commerce, as they were disseminated across state lines to consumers throughout the United States.
57. Each of the false and misleading statements described above is material to consumer purchasing decisions. Claims regarding clinical efficacy, price, and ingredient safety are among the most important factors that consumers consider when choosing acne-treatment products. The false claims have the tendency to deceive, and have actually deceived, a substantial segment of the relevant consumer audience, as evidenced by the consumer-perception survey conducted by Dr. Eleanor Fisk, which demonstrated significant shifts in consumer perceptions of DermaTrūe's pricing and efficacy following exposure to the campaign.
58. Meridian has been, and continues to be, directly and proximately injured by Apex's false advertising. Meridian has suffered lost sales, lost profits, diminished brand equity, damage to its reputation for quality and value, and loss of critical retail shelf space, all as detailed above. Meridian is likely to continue to suffer such injuries absent injunctive relief from this Court. The injuries Meridian has suffered are the type of commercial injuries that Section 43(a) of the Lanham Act was designed to prevent.
59. Apex's conduct has been willful, deliberate, and undertaken in bad faith. Apex launched its $23.0 million campaign with full knowledge that its claims were false or, at a minimum, unsubstantiated. Apex refused to cease or modify the campaign following Meridian's cease-and-desist letter, refused to comply with NAD's preliminary recommendation to discontinue or modify the clinical superiority and price-comparison claims, and has continued to disseminate the false advertisements without modification through the date of filing of this Complaint. Apex's willful conduct entitles Meridian to enhanced damages and attorneys' fees under 15 U.S.C. § 1117(a).
COUNT II
DECEPTIVE ACTS AND PRACTICES NEW YORK GENERAL BUSINESS LAW § 349
60. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.
61. Apex's false and misleading "The PuraClear Truth" advertising campaign constitutes consumer-oriented conduct that is deceptive and misleading in a material way, in violation of New York General Business Law § 349. The campaign is directed at consumers at large and is designed to influence their purchasing decisions through false representations regarding the clinical efficacy, pricing, and ingredient safety of PuraClear products relative to DermaTrūe products.
62. Apex's deceptive acts and practices were directed at consumers and had a broad impact on consumers at large in the State of New York and throughout the United States. The campaign was disseminated through mass media channels — including national television, digital platforms, in-store displays at retail locations in New York, and print media distributed in New York — and was designed to reach millions of consumers, including consumers in New York who are purchasers or potential purchasers of acne-treatment products.
63. The deceptive acts and practices alleged herein are likely to mislead a reasonable consumer acting reasonably under the circumstances. The claims at issue — a purported peer-reviewed clinical study, a side-by-side price comparison, and a comparative ingredient claim — are presented in a manner that a reasonable consumer would accept at face value and that would materially influence such a consumer's purchasing decision.
64. Meridian has suffered injury as a result of Apex's deceptive practices, including but not limited to lost sales, lost profits, diminished brand equity, and loss of retail shelf space, as set forth in detail above. Pursuant to New York General Business Law § 349(h), Meridian is entitled to recover its actual damages, or fifty dollars, whichever is greater, as well as treble damages up to one thousand dollars, reasonable attorneys' fees, and costs.
COUNT III
FALSE ADVERTISING NEW YORK GENERAL BUSINESS LAW § 350
65. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.
66. Apex's "The PuraClear Truth" advertising campaign constitutes advertising that is false, misleading, and deceptive within the meaning of New York General Business Law § 350. The campaign contains representations and statements of fact that are untrue, deceptive, and misleading, including the fabricated clinical superiority claim, the misleading price comparison, and the false "clean" ingredients claim, each of which is described in detail above.
67. The false advertisements specifically target and disparage Meridian's DermaTrūe products by name through literally false claims and materially misleading comparisons. The false advertising was disseminated in New York through national television broadcasts received in New York, digital advertisements served to New York consumers, in-store displays at drugstore locations in New York, and print media distributed in New York, and through a publicly accessible campaign website.
68. Meridian has been injured by Apex's false advertising through lost sales, lost profits, diminished brand value, damage to consumer trust, and loss of retail shelf space, as set forth in detail above. Pursuant to New York General Business Law § 350-e, Meridian is entitled to recover compensatory damages, or five hundred dollars, whichever is greater, and reasonable attorneys' fees.
COUNT IV
COMMON-LAW UNFAIR COMPETITION
69. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.
70. Apex's conduct, as alleged herein, constitutes unfair competition under the common law of the State of New York. By conceiving, developing, funding, and disseminating a nationwide false and misleading comparative advertising campaign that expressly targets Meridian's DermaTrūe products by name, Apex has engaged in deceptive, dishonest, and unethical commercial practices designed to misappropriate Meridian's market share, divert Meridian's customers and revenue, and gain an unfair competitive advantage through misrepresentations of material fact. Apex's conduct goes beyond legitimate competitive activity and constitutes the type of commercial immorality that the law of unfair competition is designed to prevent.
71. Apex's conduct was undertaken in bad faith and with the deliberate intent to injure Meridian, to deceive consumers, and to misappropriate the substantial goodwill that Meridian has built in its DermaTrūe brand through years of investment in product development, marketing, and consumer trust. Apex's willingness to invest $23.0 million in a campaign built on fabricated studies, misleading price comparisons, and false ingredient claims demonstrates a calculated and premeditated scheme to advance Apex's commercial interests at Meridian's expense through dishonest means.
72. Meridian has been damaged as a direct and proximate result of Apex's unfair competitive practices, including through lost sales and profits, diminished brand equity and goodwill, damage to consumer trust, and loss of retail shelf space, all as detailed above. Meridian is entitled to recover compensatory damages, disgorgement of Apex's profits, and injunctive relief.
COUNT V
TORTIOUS INTERFERENCE WITH BUSINESS RELATIONS
73. Plaintiff Meridian Consumer Brands LLC incorporates by reference the allegations contained in all preceding paragraphs of this Complaint as if fully set forth herein.
74. Meridian had existing and prospective business relationships with its retail customers and distribution partners, including but not limited to Kingsley Drug Stores LLC, a major national retail chain operating more than 2,400 stores across 42 states. Meridian's relationship with Kingsley dates back to 2015 and has been a significant and valuable component of Meridian's retail distribution network. Meridian also maintains business relationships with numerous other national and regional retailers that carry and sell DermaTrūe products, each of which constitutes a valuable business relationship that has been placed at risk by Apex's conduct.
75. Apex knew, or should have known, of Meridian's business relationships with its retail customers, including Kingsley Drug Stores LLC and other major retail chains. Meridian's retail distribution network is a matter of public knowledge in the industry, and DermaTrūe products are prominently displayed in thousands of retail locations nationwide. Moreover, Apex, as a direct competitor of Meridian in the acne-treatment market, has intimate knowledge of Meridian's retail distribution channels, as both companies compete for shelf space at many of the same retail chains.
76. Apex intentionally and improperly interfered with Meridian's business relationships with its retail customers through the deliberate dissemination of its false and misleading "The PuraClear Truth" advertising campaign. The false claims contained in the campaign caused consumers to lose confidence in DermaTrūe products, which in turn caused consumer demand for DermaTrūe products to decline, which in turn caused retailers to reduce or threaten to terminate their business with Meridian. The interference was accomplished through wrongful means — specifically, through the dissemination of false and misleading advertising that violates federal and state law — and was motivated by Apex's desire to gain an unfair competitive advantage at Meridian's expense.
77. As a direct and proximate result of Apex's tortious interference, on August 5, 2025, Kingsley Drug Stores LLC formally notified Meridian that it was reducing DermaTrūe shelf space by 30% effective October 1, 2025. Kingsley cited "declining consumer demand" for DermaTrūe products as the primary reason for the shelf-space reduction — demand that declined as a direct and proximate result of Apex's false and misleading campaign.
78. Meridian estimates the annual revenue impact of the Kingsley shelf-space reduction at approximately $4.1 million. The harm extends beyond this direct revenue impact, as the shelf-space reduction diminishes DermaTrūe's retail visibility, reduces consumer access to DermaTrūe products, and may trigger similar reductions by other retail partners.
79. But for Apex's wrongful conduct, Kingsley Drug Stores LLC would not have reduced DermaTrūe shelf space, and Meridian would have continued to enjoy its prior level of business with Kingsley. Similarly, but for Apex's wrongful conduct, Meridian's business relationships with other retailers would not have been impaired, and Meridian would not have suffered the decline in consumer demand and brand perception that has damaged its retail partnerships. Meridian is entitled to recover compensatory damages for the harm caused by Apex's tortious interference.
PRAYER FOR RELIEF
WHEREFORE, Plaintiff Meridian Consumer Brands LLC respectfully requests that this Court enter judgment in its favor and against Defendant Apex Naturals Inc. and award Plaintiff the following relief:
(a) Preliminary Injunction: Enter a preliminary injunction, pursuant to Rule 65 of the Federal Rules of Civil Procedure, ordering Defendant Apex Naturals Inc. to immediately cease all dissemination of "The PuraClear Truth" campaign materials across all media channels, including but not limited to national television, digital video platforms (Crowne Albany Partners LLC, Dunmore & Co., Northpoint Services Inc. Reels, and all other digital and social media platforms), in-store point-of-sale displays, print advertisements, and the internet; to immediately remove the campaign page located at www.apexnaturals.com/puraclear-truth and all related content from Apex's website; and to refrain from making the clinical superiority claim, the price-comparison claim, the "clean" ingredients claim, or any substantially similar claims, in any medium, pending final adjudication of this action;
(b) Permanent Injunction: Enter a permanent injunction permanently enjoining Defendant Apex Naturals Inc., and its officers, directors, employees, agents, representatives, successors, assigns, and all persons acting in concert or participation with them, from disseminating any of the false and misleading claims identified herein, or any substantially similar claims, in any medium, and from engaging in any false advertising or deceptive trade practices directed at Meridian or Meridian's products;
(c) Corrective Advertising: Order Defendant Apex Naturals Inc. to fund and disseminate corrective advertising, at Apex's sole expense, in a form, scope, duration, and through media channels to be determined by the Court, sufficient to dispel the false impressions created by "The PuraClear Truth" campaign among consumers and the trade;
(d) Compensatory Damages: Award Plaintiff Meridian Consumer Brands LLC compensatory damages for lost profits and other economic losses caused by Defendant's false advertising, in an amount to be proven at trial, preliminarily estimated at $18.5 million on an annualized basis;
(e) Disgorgement of Profits: Award Plaintiff Meridian Consumer Brands LLC disgorgement of Defendant Apex Naturals Inc.'s profits attributable to the false advertising campaign, in an amount to be proven at trial, preliminarily estimated at $11.2 million, based on estimated incremental PuraClear revenue of $19.8 million at an estimated gross margin of 56.5%;
(f) Treble Damages: Award treble damages pursuant to 15 U.S.C. § 1117(a) in light of Defendant's willful and deliberate conduct, in an amount up to $55.5 million ($18.5 million × 3), or such greater amount as may be proven at trial;
(g) Attorneys' Fees and Costs: Award Plaintiff Meridian Consumer Brands LLC its reasonable attorneys' fees and costs of suit incurred in connection with this action, pursuant to 15 U.S.C. § 1117(a) and applicable provisions of New York law, this being an exceptional case warranting such an award;
(h) Prejudgment and Post-Judgment Interest: Award Plaintiff Meridian Consumer Brands LLC prejudgment interest from the date of the first actionable wrong and post-judgment interest from the date of judgment, at the highest rates permitted by applicable law; and
(i) Other Relief: Grant such other and further relief as this Court deems just, equitable, and proper.
DEMAND FOR JURY TRIAL
Plaintiff Meridian Consumer Brands LLC hereby demands a trial by jury on all claims and issues so triable in this action, pursuant to Rule 38 of the Federal Rules of Civil Procedure and the Seventh Amendment to the United States Constitution.
VERIFICATION
I, Derek Cho, declare and state as follows:
1. I am the General Counsel of Meridian Consumer Brands LLC, the Plaintiff in this action. I am authorized to make this verification on behalf of Meridian Consumer Brands LLC.
2. I have read the foregoing Verified Complaint for Injunctive Relief, Damages, and Other Relief. The factual allegations contained therein are true and correct to the best of my knowledge, information, and be